Skip to main content
Premium Trial:

Request an Annual Quote

Cisbio, Blue Sky Collaborate on Kinase Assay Development

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cisbio Bioassays and Blue Sky BioProducts today announced a partnership combining their technologies for the development of assays for target kinases.

The partnership will combine Cisbio's homogenous time resolved fluorescence technology, or HTRF, with Blue Sky's TDA 2.0 technology. TDA 2.0 is a stable solution of lipid-based nanoparticles with nickel-chelating moieties and serves as a template for the assembly of purified His-tagged proteins normally associated with membranes, Cisbio said in a statement.

The deal is expected to result in assays with "unparalleled sensitivity for obtaining better biologically enhanced results on target kinases," Cisbio said.

"Through HTRF, Cisbio Bioassays has developed extensive expertise in the field of kinase enzyme screening tools," said François Degorce, director of marketing and communications for Cisbio. "The combination of these two proven technologies in this area allows us to provide an even more robust and efficient solution for studying these key therapeutic targets, particularly in oncology research."

Based in Worcester, Mass., Blue Sky provides contract research organization services to pharmaceutical firms.

Terms of the deal were not disclosed.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.